Mirum Pharmaceuticals, Inc. MIRM Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s additional paid-in capital?
- Mirum Pharmaceuticals, Inc. (MIRM) reported additional paid-in capital of $1.7B in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s additional paid-in capital changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s additional paid-in capital increased by 90.5% year-over-year, from $892.37M to $1.7B.
- What is the long-term trend for Mirum Pharmaceuticals, Inc.'s additional paid-in capital?
- Over 5 years (2020 to 2025), Mirum Pharmaceuticals, Inc.'s additional paid-in capital has grown at a 23.3% compound annual growth rate (CAGR), from $345.18M to $981.88M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.